Cardinal Health (CAH) Q1 FY2027 Earnings Call: Q&A Summary

Q: Erin Wilson Wright with Morgan Stanley asked about underlying demand trends in Pharma Distribution, specifically excluding renewals and Solaris, and if generics or other areas are evolving better than expected.

A: Jason Hollar reported strong unit demand across Specialty and generics, noting Specialty grew in the high teens, above expectations, particularly in urology and oncology. He added that generics volume was strong, supported by Red Oak, and the Solaris integration is on track.

Q: Elizabeth Anderson with Evercore ISI asked about the drivers of strength in the Other segment, specifically regarding customer acceptance and if early deal synergies are contributing.

A: Jason Hollar attributed strength to secular trends and smart growth execution, noting that at-Home, nuclear, and OptiFreight are all performing well. He highlighted that integrations like Strive are on track and the company expects growth to accelerate throughout the year.

Q: Michael Cherny with Leerink Partners asked how the different pieces of the business, such as distribution and MSO, create a greater than the sum of its parts dynamic, using urology as an example.

A: Jason Hollar described the Specialty strategy as a virtuous cycle where different business units support each other. He explained that urology is a key example where distribution, MSO, and nuclear capabilities connect to provide a comprehensive solution for physicians.

Q: George Hill with Deutsche Bank asked about the impact of the finalized OPPS rule and 340B reimbursement changes on the provider space and if it might lead to a mix shift benefiting the company's MSOs.

A: Jason Hollar stated that while hospitals will need to manage these changes, the company anticipates potentially picking up volume if patients seek care elsewhere. He noted it is premature to quantify the impact but the company will monitor it closely.

Q: Allen Lutz with Bank of America asked how the pipeline for adding urologists is progressing and how the pitch to urologists differs from other specialties like oncology.

A: Jason Hollar explained that community physicians prioritize patient care and business efficiency, and the company's value proposition resonates across different therapeutic areas. He noted that urology is more fragmented than oncology, offering significant opportunities for consolidation, provided the company maintains high-quality integration.

Q: Lisa Gill with JPMorgan asked about the regulatory environment in D.C. and potential impacts on reimbursement, specifically regarding 340B and the broader landscape for calendar 2027.

A: Jason Hollar emphasized that the company does not believe the administration intends to harm community providers, which are the lowest-cost form of care. He noted that even if legislation impacts providers, the company has a diverse payer set and low potential impact, and they remain actively engaged with policymakers.

Q: Eric Percher with Nephron Research asked if Red Oak benefits continue to accumulate and if there is any change regarding the extension of the distribution agreement.

A: Jason Hollar stated that Red Oak provides ongoing value in both dollars and service levels, and the company expects the relationship to continue beyond 2029. Aaron Alt added that the company expects a nice benefit from loss of exclusivity events, particularly in 2029 and beyond.

Q: Kevin Caliendo with UBS asked about future M&A plans, specifically if the company is interested in clinical trial opportunities or further expansion in home care, and where they see the most leverageable assets.

A: Jason Hollar clarified that the company is not looking for a fourth leg of the stool but sees ample opportunity within existing segments like Specialty and at-Home. Aaron Alt added that the company has strong cash flow and financial flexibility to support these investments while maintaining capital allocation discipline.